What is Kangstem Biotech Co., Ltd.'s (217730.KQ) StockRank?

MoatMap's StockRank for Kangstem Biotech Co., Ltd. (217730.KQ) is 18/100, with a Strong Sell signal. This is a composite score combining Quality (33), Value (37), and Momentum (37) factor ranks across MoatMap's 20,000+ stock universe.

Does Kangstem Biotech Co., Ltd. have an economic moat?

Kangstem Biotech Co., Ltd. (217730.KQ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Kangstem Biotech Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Kangstem Biotech Co., Ltd. (217730.KQ) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Kangstem Biotech Co., Ltd. in?

Kangstem Biotech Co., Ltd. (217730.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

217730.KQ

STRONG SELLREMOVE

Kangstem Biotech Co., Ltd. · Healthcare · South Korea · $189M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-47.9%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Kangstem Biotech is a South Korean clinical-stage biotechnology firm. It lacks commercialized products, stable cash flows, or any alignment with our high-conviction macro themes.

COMPANY DESCRIPTION

Kangstem Biotech Co., Ltd. is a South Korean biotechnology company focused on developing stem cell therapies for autoimmune and inflammatory diseases, such as atopic dermatitis and osteoarthritis. The company's competitive moat is built on its proprietary SELASTEC platform, which enables the mass production of high-purity umbilical cord blood-derived stem cells. Kangstem Biotech operates as a specialized niche player in the advanced regenerative medicine sector.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	11M	8M	5M	2M	-39.7%
EPS	-0.25	-0.30	-0.07	-0.10	—
Shares	52M	67M	67M	94M	+80.1%
Debt	9M	9M	6M	6M	-11.1%
Equity	32M	32M	28M	45M	11.6%
Op CF	-12M	-11M	-12M	-8M	—
Inv CF	11M	-2M	10M	-16M	—
Fin CF	-152,318	13M	582,039	23M	—

PRICE (1M)-32.8%

SMA 50SMA 200

$1.64

RSI (14)

27.0

52W High

$3.09

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

-13.6%31.6

ROE

-47.9%18.4

GP/Assets

1.1%12.8

Op. Margin

-567.7%9.9

FCF/Assets

-9.7%28.4

Piotroski

—28.7

Int. Cover

-20.2x19.7

D/E Ratio

0.15x58.4

Current Ratio

7.29x81.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-25.6x89.3

P/FCF

—N/A

P/B

3.7x32.3

P/S

168.9x5.6

Div Yield

—N/A

Momentum

52W High %

53%27.9

RS 6M

-61%17.6

SMA 50/200

1.51x98.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$189M

P/E (Forward)

—

Gross Margin

63.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 217730.KQ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
217730.KQ	Kangstem Biotech Co., Ltd.(you)	$189M	18	STRONG SELL
314130.KQ	Genome & Company	$146M	16	STRONG SELL
115450.KQ	HLB Therapeutics Co.,Ltd.	$147M	15	STRONG SELL
389650.KQ	NEXTBIOMEDICAL	$217M	12	STRONG SELL
215600.KQ	SillaJen, Inc.	$233M	13	STRONG SELL
138610.KQ	NIBEC Co., Ltd.	$141M	14	STRONG SELL
365270.KQ	curacle co.,ltd.	$165M	25	SELL
086820.KQ	Biosolution Co.,Ltd.	$127M	21	SELL
228760.KQ	Genomictree Inc.	$216M	9	STRONG SELL
308080.KQ	ViGenCell Inc.	$135M	12	STRONG SELL

Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.4%

Kangstem Biotech Co., Ltd. (217730.KQ) — Stock Score Summary

Kangstem Biotech Co., Ltd. (217730.KQ) has a MoatMap StockRank of 18/100 based on Quality (33/100), Value (37/100), and Momentum (37/100) factor scores. The current signal is STRONG SELL. Kangstem Biotech is a South Korean clinical-stage biotechnology firm. It lacks commercialized products, stable cash flows, or any alignment with our high-conviction macro themes.

Key Financial Metrics

Price	$1.64
Market Cap	$189M
Price/Book	3.69
Return on Equity	-47.9%
Return on Invested Capital	-13.6%
Debt/Equity	15.13
Gross Margin	63.2%
Operating Margin	-567.7%
Revenue Growth	-15.6%
Free Cash Flow	$-4K

Kangstem Biotech Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Kangstem Biotech Co., Ltd.’s (217730.KQ) StockRank?: MoatMap’s StockRank for Kangstem Biotech Co., Ltd. (217730.KQ) is 18/100, with a Strong Sell signal. It is a composite of Quality (33), Value (37), and Momentum (37) factor ranks across MoatMap’s 20,000+ stock universe.
Does Kangstem Biotech Co., Ltd. have an economic moat?: Kangstem Biotech Co., Ltd. (217730.KQ) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kangstem Biotech Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Kangstem Biotech Co., Ltd. (217730.KQ) is Strong Sell, based on a StockRank of 18/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kangstem Biotech Co., Ltd. in?: Kangstem Biotech Co., Ltd. (217730.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).